Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
The drug has been approved in Europe and the US as a treatment for HIV/AIDS but does not yet have regulatory approval anywhere in the world as an HIV prevention drug. Once approved, producing enough ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...
It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback